Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/15094
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHawken, S-
dc.contributor.authorKwong, JC-
dc.contributor.authorDeeks, SL-
dc.contributor.authorCrowcroft, NS-
dc.contributor.authorMcGeer, AJ-
dc.contributor.authorDucharme, R-
dc.contributor.authorCampitelli, MA-
dc.contributor.authorCoyle, D-
dc.contributor.authorWilson, K-
dc.date.accessioned2017-08-30T15:42:11Z-
dc.date.available2015-02-01-
dc.date.available2017-08-30T15:42:11Z-
dc.date.issued2015-
dc.identifier.citationEMERGING INFECTIOUS DISEASES, 2015, 21 (2), pp. 224 - 231 (8)en_US
dc.identifier.issnhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000348491400005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=f12c8c83318cf2733e615e54d9ed7ad5-
dc.identifier.issnhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000348491400005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=f12c8c83318cf2733e615e54d9ed7ad5-
dc.identifier.issn1080-6040-
dc.identifier.issn1080-6059-
dc.identifier.urihttp://bura.brunel.ac.uk/handle/2438/15094-
dc.description.abstractIt is unclear whether seasonal influenza vaccination results in a net increase or decrease in the risk for Guillain-Barré syndrome (GBS). To assess the effect of seasonal influenza vaccination on the absolute risk of acquiring GBS, we used simulation models and published estimates of age- and sex-specific risks for GBS, influenza incidence, and vaccine effectiveness. For a hypothetical 45-year-old woman and 75-year-old man, excess GBS risk for influenza vaccination versus no vaccination was –0.36/1 million vaccinations (95% credible interval –1.22% to 0.28) and –0.42/1 million vaccinations (95% credible interval, –3.68 to 2.44), respectively. These numbers represent a small absolute reduction in GBS risk with vaccination. Under typical conditions (e.g. influenza incidence rates >5% and vaccine effectiveness >60%), vaccination reduced GBS risk. These findings should strengthen confidence in the safety of influenza vaccine and allow health professionals to better put GBS risk in context when discussing influenza vaccination with patients.en_US
dc.format.extent224 - 231 (8)-
dc.languageEnglish-
dc.language.isoenen_US
dc.publisherCENTERS DISEASE CONTROLen_US
dc.subjectScience & Technologyen_US
dc.subjectLife Sciences & Biomedicineen_US
dc.subjectImmunologyen_US
dc.subjectInfectious Diseasesen_US
dc.subjectPRACTICE RESEARCH DATABASEen_US
dc.subjectHEALTH-CARE WORKERSen_US
dc.subjectSEASONAL INFLUENZAen_US
dc.subjectUNITED-KINGDOMen_US
dc.subjectA H1N1en_US
dc.subjectVACCINESen_US
dc.subjectSURVEILLANCEen_US
dc.subjectASSOCIATIONen_US
dc.subjectCANADAen_US
dc.subjectCAMPYLOBACTERen_US
dc.titleSimulation Study of the Effect of Influenza and Influenza Vaccination on Risk of Acquiring Guillain-Barre Syndromeen_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.3201/eid2102.131879-
dc.relation.isPartOfEMERGING INFECTIOUS DISEASES-
pubs.issue2-
pubs.publication-statusPublished-
pubs.volume21-
Appears in Collections:Publications

Files in This Item:
File Description SizeFormat 
Fulltext.pdf536.86 kBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.